These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 34207069)
21. PSMA Theranostics: Science and Practice. Mokoala K; Lawal I; Lengana T; Kgatle M; Giesel FL; Vorster M; Sathekge M Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359805 [TBL] [Abstract][Full Text] [Related]
22. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Heidegger I; Kesch C; Kretschmer A; Tsaur I; Ceci F; Valerio M; Tilki D; Marra G; Preisser F; Fankhauser CD; Zattoni F; Chiu P; Puche-Sanz I; Olivier J; van den Bergh RCN; Kasivisvanathan V; Pircher A; Virgolini I; Gandaglia G Ther Adv Med Oncol; 2022; 14():17588359221081922. PubMed ID: 35273651 [TBL] [Abstract][Full Text] [Related]
23. PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. El Fakiri M; Geis NM; Ayada N; Eder M; Eder AC Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439121 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of [ Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003 [TBL] [Abstract][Full Text] [Related]
26. Influence of short-term dexamethasone on the efficacy of Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729 [TBL] [Abstract][Full Text] [Related]
27. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8 Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Gafita A; Fendler WP; Hui W; Sandhu S; Weber M; Esfandiari R; Calais J; Rauscher I; Rathke H; Tauber R; Delpassand ES; Weber WA; Herrmann K; Czernin J; Eiber M; Hofman MS Eur Urol; 2020 Aug; 78(2):148-154. PubMed ID: 32532512 [TBL] [Abstract][Full Text] [Related]
29. Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. Marshall CH; Antonarakis ES Cancer Treat Res Commun; 2020 Jan; 23():100164. PubMed ID: 31978677 [TBL] [Abstract][Full Text] [Related]
30. Dawn of Theranostics in Myanmar (Dream, Reality, and Constraint). Myint K; Thein TM; Phyu TK; Maung W Nucl Med Mol Imaging; 2019 Feb; 53(1):42-46. PubMed ID: 30828400 [TBL] [Abstract][Full Text] [Related]
31. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy. Zhang J; Kulkarni HR; Singh A; Baum RP Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261 [TBL] [Abstract][Full Text] [Related]
32. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618 [TBL] [Abstract][Full Text] [Related]
33. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365 [TBL] [Abstract][Full Text] [Related]
34. Prostate-specific membrane antigen theranostics: therapy with lutetium-177. Ferdinandus J; Violet J; Sandhu S; Hofman MS Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583 [TBL] [Abstract][Full Text] [Related]
35. Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285 [TBL] [Abstract][Full Text] [Related]
37. Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with von Eyben FE; Kulkarni HR; Baum RP Theranostics; 2020; 10(11):4900-4902. PubMed ID: 32308757 [TBL] [Abstract][Full Text] [Related]
38. Third-line treatment and von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908 [TBL] [Abstract][Full Text] [Related]